StemCell Therapy

LAK Cells with Low Dose of Interleukin-2 in Patients with Solid Tumors

One of the procedures involves the separation of lymphocytes from the peripheral blood, culturing them in the patients own blood serum and expanding their numbers multifold before transfusing them back to the patient to yield maximum results.

The stem cell procedure that we administer consists of the stimulation of lymphocytes in vivo. During this stem cell procedure the sample is taken from the patients bone marrow of the head of the tibia bone and provides in addition to lymphocytes, stem cells, mature and immature leukocytes.

This combination renders the therapy even more powerful. As the stroma of bone marrow contains IL-7, which increases the effect of IL-2 by 5 times, we can decrease the dose of IL-2 while maintaining its potency.

Interleukin-2 stimulates the stem cells of the lymphocytes that then divide into T-Helper cells, such as THO, TH1 and TH2, which secrete lymphokines, various cytokines, such as interleukins and interferons.

TH1 secretes mainly IL-2, interferon gamma, GM-CSF, TNA-alpha, ligand CD40, which can activate macrophages. The LTC or cytotoxic CD8+ lymphocytes produce perforins, gamzymes, interferon gamma, TNF alpha and beta, and can in this way destroy circulating abnormal cells.

Stem cells are the human bodys master cells with the ability to renew themselves through cell division and grow into any one of its 200 cell types, except for cells of the placenta. They have the potential to multiply indefinitely, become highly specialized and replace cells that die or are lost.

Thus these specialized Stem Cells, aid in the repair of organs and tissue damaged by cancer progression, previous cancer treatments, or chronic degenerative conditions. They also maintain the normal turnover of regenerative organs, such as blood, skin, and intestinal tissues. Autologous Stem Cells from the patients own bone marrow do not have any adverse side effects.

Under normal conditions, we have less than 0.1% of stem cells in circulation, which is sometimes not sufficient for regenerative processes. The objective is, therefore, to increase the number of stem cells in circulation without the use of potent toxic drugs.

The immune-stimulatory effect of our therapy is sometimes quickly seen in the improvement of the overall condition of the patient, quality of life, reduction of pain, etc. Tumor shrinkage may take four weeks or longer. The procedure can be repeated after two months.

The protocols with autologous stem cells and low-dose Interleukin-2 that we administer do usually not cause any adverse effects.

Watch Video Testimonials.

Find Out More About Treatment and Costs.

Excerpt from:
Cytokines, NK Cells, LAK Cells, Stem Cells Explained

This entry was posted on June 18, 2018 at 5:54 pm and is filed under Death by Stem Cells. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |